Editas Medicine, Inc. (EDIT): Total Liabilities
$159.25M
As of 2025-12-31
$132.08M
As of 2026-06-30
+1.2%
3-year compound annual growth
-2.3%
5-year compound annual growth
+17.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $159.25M | -23.2% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $207.31M | +38.2% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $150.06M | -2.3% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $153.64M | +24.1% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $123.84M | -30.8% | 2023-02-22, Balance as of period end |
| 2020-12-31 | $179.02M | -27.4% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $246.45M | +33.8% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $184.22M | +11.5% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $165.18M | +74.7% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $94.58M | +190.4% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $32.56M | n/a | 2017-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $163.15M | +14.6% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.08M | -31.0% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $34.12M | +12.9% |
Compare EDIT, VYGR, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗